This comparative effectiveness study, conducted among a Danish nationwide cohort, compares the effectiveness and safety of vedolizumab vs tumor necrosis factor for older patients with inflammatory bowel disease (IBD). The gene discussed is TNF; the disease is inflammatory bowel disease.